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With significant deficits in early detection and poor treatment response, ovarian cancer is 
a devastating diagnosis for many women. Up to 25% of epithelial ovarian cancer (EOC) is due to 
a hereditary predisposition, most commonly in BRCA1 and BRCA2.  Pathogenic variants in 
BRCA1, for example, confer a 45% lifetime risk of EOC; whereas, the general population risk is 
only 1-2%. Knowledge of an affected individual’s genetic status can have significant implications 
for treatment and prognosis. Women with pathogenic variants in BRCA1/2 have an enhanced 
response to platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors, 
leading to an improved prognosis. Identifying individuals who harbor pathogenic variants in 
ovarian cancer predisposition genes is therefore of critical importance. 
Current National Comprehensive Cancer Network (NCCN) guidelines recommend that all 
individuals diagnosed with EOC be offered germline genetic testing. While this would ideally be 
performed by genetics professionals, a shortage of genetic counselors precludes timely access to 
these services. This study sought to investigate the current genetic testing practices of oncology 
providers in order to determine the feasibility of oncologist-led genetic testing for patients with 
EOC. A survey was distributed to members of the Society of Gynecologic Oncologists with 
questions regarding timing, frequency, and type of genetic testing, referrals to genetics 
professionals, confidence with aspects of genetics services, and any barriers that currently hinder 
these processes. Results of the study were encouraging, with the majority of providers always 
 v 
ordering genetic testing for patients with EOC; testing was most commonly ordered at diagnosis 
and was typically multi-gene panel testing that included BRCA1/2, consistent with current 
recommendations. Provider confidence with the genetic testing process was generally high, 
especially for deciding which patients to refer to genetics professionals. Patient disinterest and 
concerns for insurance coverage were commonly cited barriers to testing and referrals. Thus, 
oncologist-led genetic testing for patients with EOC, with referrals to genetics professionals when 
appropriate, has the potential to be a viable alternative service delivery model and warrants 
additional investigation.  
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Ovarian cancer is the 5th leading cause of cancer death for women in the United States, as 
difficulties in early detection and treatment response often lead to a poor prognosis. Most ovarian 
cancers are not diagnosed until advanced stages, where the 5-year survival rate is only 29%.1 
Importantly, 20-25% of epithelial ovarian cancer (EOC) is related to a hereditary predisposition.2 
The majority of pathogenic variants occur in BRCA1 and BRCA2. Mismatch repair genes related 
to Lynch syndrome such as MLH1, PMS2, MSH2, MSH6, and EPCAM also contribute to ovarian 
cancer cases, as well as other moderate-risk genes.3 Due to the high rate of germline pathogenic 
variants, current NCCN, ASCO, and SGO guidelines recommend that all women diagnosed with 
EOC be offered genetic testing.4-6  
For affected individuals, standard-of-care treatment for late-stage ovarian cancer is surgery 
and platinum-based chemotherapy. Women with pathogenic variants in BRCA1/2 or other genes 
that disrupt homologous recombination, whether germline or somatic, have favorable response to 
poly ADP-ribose polymerase (PARP) inhibitors.7 These women therefore often have an improved 
prognosis.8 Similarly, patients with pathogenic variants in mismatch repair genes have targeted 
immunotherapy treatment options and often have improved survival compared to most patients.9 
Knowledge of genetic status is therefore critical in tailoring treatments and informing prognosis.  
Current screening methods for ovarian cancer are ineffective and do not improve survival 
of patients.10,11 For women at a significantly increased risk of developing EOC, risk-reducing 
surgery is the most effective preventative measure.12 Germline genetic testing is therefore essential 
in order to identify at-risk individuals; tumor testing alone is not sufficient. Many of the genes 
implicated in ovarian cancer predispositions have additional cancer risks where additional 
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screening and risk-reducing interventions could be considered.4,13 Pathogenic variants in the 
BRCA1/2 genes substantially increase the risk for breast cancer and have additional risks for male 
breast, prostate, pancreatic, and melanoma cancers.14 In the mismatch repair genes, pathogenic 
variants result in significantly increased risks for colorectal and endometrial cancers and slightly 
increased risks for skin, gastric, bile duct, small bowel, and pancreatic cancers.13 Not only does 
this knowledge help to inform care for the patient, but at-risk family members can also be evaluated 
to clarify if their risks are elevated or at the general population level. Germline testing for ovarian 
cancer predisposition genes is therefore useful in informing patients and their families of potential 
inherited cancer risks. 
Unfortunately, there is limited capacity for patients to be seen by a genetics healthcare 
professional, and long wait times can seriously hinder appropriate testing and counseling for 
individuals.15 Certain patient characteristics have also been shown to be associated with less 
genetic testing, including Black race, greater poverty, and less insurance.16 A recent study found 
that only 35% of women with ovarian cancer have received genetic testing despite current 
guidelines.17 Comprehensive knowledge of the factors that are limiting genetic testing of patients 
with EOC are still not fully understood. In light of this issue, there has been a call to mainstream 
germline genetic testing by oncologists for patients with EOC. Studies in the United Kingdom 
have shown favorable outcomes with this service delivery model including high patient and 
provider satisfaction, rapid turnaround time, and appropriate referrals.18,19 It is not only critical that 
oncologists order appropriate testing and utilize the results to guide treatment, but they must also 
refer patients with positive or unclear results to genetics services to ensure comprehensive care. 
This study sought to investigate the current practices for genetic testing in patients 
diagnosed with EOC by oncology providers. A survey was sent to members of the Society of 
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Gynecologic Oncologists, including oncologists, physician assistants, and nurses. Information 
collected included the type, frequency, and timing of genetic testing as well as referrals to genetics 
providers and questions to elucidate barriers to testing and referrals.  
The specific aims of this study were as follows: 
a) To assess the current practices of oncology providers regarding the ordering and 
use of genetic testing in patients with epithelial ovarian cancer  
b) To identify the frequency with which oncology providers make referrals to genetics 
professionals for their patients 
c) To evaluate the prevalence and types of genetics education that oncology providers 
have received  
d) To identify the comfort level of oncology providers with different aspects of cancer 
genetics services 
The results of this study will help to identify successes and barriers that currently exist in 
the United States regarding the mainstreaming of genetic testing for patients with EOC. Future 
studies can further investigate ways to streamline this pathway, address any issues that exist, and 
improve the patient experience. 
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2.0 Literature Review 
2.1 Ovarian Cancer 
In 2018, the World Health Organization (WHO) estimated the incidence of ovarian cancer 
diagnoses to be 295,414 globally; at the same point in time, there were 184,799 new ovarian cancer 
deaths.20 In the United States alone, the incidence of ovarian cancer is 14.8 in 100,000 women.21 
Most women are diagnosed after menopause; it is rare for women under the age of 40 to have 
ovarian cancer.22 As the 5th leading cause of cancer death in women, the 5-year survival rate for 
invasive ovarian cancer at all stages is 47%. For metastatic stages—which compromises 59% of 
diagnoses—the 5-year survival rate drops to 28%.1 
2.1.1 Screening and Surveillance 
A deficit in the ability to detect ovarian cancer early results in most women being diagnosed 
at later stages of the disease, contributing to a poor prognosis. When still localized, the 5-year 
survival rate of ovarian cancer is 92%.1 Vague and non-specific symptoms such as frequent 
urination, feeling full quickly, abdominal pain, and bloating can arise, but these often do not 
present until advanced stages of the disease, if at all.10  Attempts to detect ovarian cancer earlier 
through screening measures have been studied. A randomized control trial with 78,216 average-
risk women either receiving normal gynecologic care or an annual transvaginal ultrasound 
combined with cancer antigen 125 (CA-125) screening did not result in a decrease in mortality nor 
a stage shift. Additionally, the screening program had a false positive rate of 5%, and the invasive 
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diagnostic follow-up procedure resulted in serious medical complications in 15% of the study 
participants.10 
Some screening studies have found evidence of a slight increase in early detection of 
ovarian cancer. A randomized control trial with average-risk women in Japan found that a higher 
proportion of women were diagnosed at Stage I in the screening group (63%) compared to the 
control group (38%), but this difference was not statistically significant.23 Additional studies have 
examined serial CA-125 screening with scores using the Risk of Ovarian Cancer Algorithm 
(ROCA) in either average-risk women or women with a significant family history or a BRCA1/2 
pathogenic variant.11,24-26 ROCA utilizes CA-125 data from thousands of women to determine the 
risk of having ovarian cancer based on CA-125 fluctuations. The researchers obtained a baseline 
CA-125 level for each woman, and ROCA was recalculated with every serial CA-125 value. If 
ROCA demonstrated an elevated risk for ovarian cancer, then a transvaginal ultrasound was 
performed. There was no reduction in mortality for average-risk women, and the program was not 
cost-effective.11,25,26 For high-risk women, there was a significant increase in the detection of early-
stage ovarian cancer compared to historical controls as well as a low false positive rate, but the 
data are not sufficient to replace the current recommendation for high-risk women to undergo a 
risk-reducing salpingo-oophorectomy (RRSO).24  
2.1.2 Histological Subtypes  
Ovarian cancer is a heterogenous disease with different histologic subtypes. First, ovarian 
cancer types can be broken down by the cell from which it originates: epithelial (90% of cases), 
sex-cord stromal, germ cell, and mixed-cell type.27 Epithelial ovarian cancer can be further broken 
down into multiple histological subtypes (Table 1).27-31 Information on the histological subtype is 
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pivotal to understand relevant risk factors and best treatment approaches. The WHO classifies 
ovarian tumors into one of two types. Type I tumors notably include low-grade serous, 
endometrioid, clear cell, and mucinous carcinomas; these tumors are typically low grade and have 
a slow progression. Rarely, type I tumors can be malignant Brenner or seromucinous. Somatic 
variants in these tumors typically involve KRAS and BRAF.27 The type II category encompasses 
high-grade serous carcinomas, carcinosarcomas, and undifferentiated carcinomas. These tumors 
often progress rapidly and aggressively, and they are likely to carry somatic variants in TP53 as 
well as somatic or germline variants in BRCA1/2.2,27,32 
Table 1 Distribution of histological subtype of invasive epitheical ovarian carcinomas  
Type Histological Subtype Estimated Prevalence 
I 
Low-grade serous 3.5% 
Endometroid 11% 
Clear cell 12% 
Mucinous 3.5% 
Other 2% 
II High-grade serous 68% 
 Other Rare 
 
2.1.3 Risk and protective factors for epithelial ovarian cancer 
For a woman living in the United States, the average lifetime risk of developing epithelial 
ovarian cancer is 1-2%.33,34 However, there are several factors that are known to increase or 
decrease the risk of EOC. Li et al. (2015) created an epidemiologic risk prediction model using 
data from 202,206 Western European women. Although this model has never been validated, it 
does provide insight into potential risk and protective factors, many of which have been supported 
by other studies.35 Certain factors have only been shown to have an association with particular 
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histological subtypes, which emphasizes the importance of understanding the etiology of ovarian 
cancer subtypes (Table 2).  
 
Table 2 Risk and protective factors for invasive epithelial ovarian cancer 
Evidence Level Risk Factor Protective Factor 
Strong 
Family history of ovarian cancer34,36 
Hormone replacement therapy35,37 










Older age at menopause35,45 








infertility drugs54,55, polycystic 
ovary syndrome (PCOS)56, pelvic 
inflammatory disease (PID)57, 
alcohol58 
Multiple births59, hysterectomy43,45 
 
For family history, the increase in risk for EOC depends on the degree of relation to the 
affected family member, as well as the number of family members affected. A woman with an 
affected first degree relative is about three times more likely to develop ovarian cancer than a 
woman without this family history.34,36 If a woman has more than one affected first-degree relative, 
she is 10 times more likely to develop ovarian cancer.60 BRCA1/2 pathogenic variants are estimated 
to account for a quarter of the familial relative risk for first-degree relatives. Other factors that 
increase familial relative risk include having affected relatives with EOC diagnosed under 50 years 
old and affected relatives with serous histology.36,60  
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Surgical removal of the ovaries is currently recommended for women at an increased risk 
of ovarian cancer because it is the strongest protective factor.4 RSSO has been shown to 
dramatically reduce the risk of ovarian cancer in multiple studies, with risk reduction estimates 
around 80%.43,44  Oral contraceptive use is also an established protective factor. A meta-analysis 
that combined results from 45 epidemiological studies found that the use of oral contraceptives 
reduces a woman’s risk for ovarian cancer by 27% compared to women who reported never using 
them. Moreover, the longer the duration of use, the lower her risk; taking oral contraceptives for 
at least five years reduces the  risk of developing ovarian cancer by approximately 50%.41 Further 
research is still needed to clarify risk estimates with knowledge of genetic predispositions and 
establish more evidence for factors that are currently not well supported.  
2.2 Genetic Predispositions to Ovarian Cancer 
Several genes have been identified to be associated with an increased susceptibility to 
EOC.61-65 It is currently estimated that about 20-25% of ovarian cancer is due to a hereditary 
predisposition.2,66  BRCA1 and BRCA2 pathogenic variants account for the majority of hereditary 
ovarian carcinomas, followed by pathogenic variants related to Lynch syndrome.3,9,61,62,66 Other 
genes have been shown to contribute moderately to EOC risk such as RAD51D, RAD51C, BRIP1, 
BARD1, and PALB2, among others.63,64 Germline genetic testing can identify unaffected 
individuals who would benefit from preventative strategies; it can also help to direct treatment, 
inform prognosis, and elucidate additional beneficial screening for affected individuals. Current 
NCCN guidelines recommend that any woman with a diagnosis of epithelial ovarian, fallopian 
tube, and/or peritoneal cancers be offered germline genetic testing.7 
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2.2.1   BRCA1 and BRCA2 
Both BRCA1 and BRCA2 are associated with the autosomal dominant Hereditary Breast 
and Ovarian Cancer (HBOC) syndrome. These genes are necessary for double-stranded DNA 
breaks to be repaired by homologous recombination.61 Several studies have aimed to quantify the 
frequency of BRCA1/2 germline pathogenic variants in women with ovarian cancer. A case-control 
study in Australia with 1,001 women found germline BRCA1/2 pathogenic variants in 14.1% of 
patients with non-mucinous ovarian carcinomas. When only looking at patients with high-grade 
serous histology, this prevalence increased to 22.6%.61 A prospective cohort study of 104 patients 
with EOC found that 21.15% of patients carried BRCA1/2 pathogenic variants, and patients with 
high-grade serous histology had a higher prevalence (25.7%) of these variants.67 One study 
specifically sought to estimate the prevalence of BRCA1/2 variants in an ethnically diverse sample 
of 585 patients with EOC and found that 22.5% carried a pathogenic variant, again with a higher 
prevalence (27.6%) in those with a serous histology.68 Importantly, not all patients identified to 
have a pathogenic variant in BRCA1/2 had a reported family history of breast or ovarian cancer. 
44% of patients in the Australia study had no suggestive family history at all.61 This study, and 
many others, are consistently finding that family history is not sufficient to predict pathogenic 
variant status; this supports current NCCN guidelines to offer genetic testing to any woman with 
epithelial ovarian cancer, regardless of family history.3,7,61,62,66-69 
For the general population, the lifetime risk of ovarian cancer is only 1-2% with an average 
age of diagnosis of 63 years old.22,33,34 In the largest prospective cohort study to date, researchers 
estimated age-specific risks for breast, ovarian, and contralateral breast cancer in BRCA1/2 
pathogenic variant carriers. The cumulative lifetime risk (to age 80) of ovarian cancer for a BRCA1 
carrier was 44%, while for BRCA2 it is around 17%.70 The average age of diagnosis for ovarian 
 10 
cancer also differs between the two genes, with BRCA1 pathogenic variant carriers typically being 
diagnosed at younger ages.66-68,70  BRCA1 carriers have a median age of diagnosis of ovarian cancer 
of 54 years compared to approximately 60 years for BRCA2.70 Importantly, other cancer risks exist 
for BRCA1/2 pathogenic variant carriers. Perhaps most notable is the lifetime breast cancer risk, 
which can be as high as 87%; other associated cancers include male breast, prostate, pancreatic, 
and melanoma.14 The benefit of identifying BRCA1/2 germline pathogenic variants is thus 
apparent, as surveillance and risk-reducing strategies could detect cancer at earlier stages or 
decrease the risk of developing many of these cancers.  
2.2.2 Mismatch repair genes 
Germline pathogenic variants in certain mismatch repair (MMR) genes—MLH1, PMS2, 
MSH2, and MSH6— and EPCAM are associated with Lynch syndrome, another autosomal 
dominant cancer predisposition syndrome. While the main cancer risks are colorectal and 
endometrial, there is an increased risk of ovarian cancer as well, along with skin, gastric, bile duct, 
small bowel, and pancreatic cancers.13,71 One study that sequenced germline DNA from 1,915 
women with ovarian cancer found that 0.4% of ovarian cancer patients had pathogenic variants in 
MMR genes.72 The lifetime risk of ovarian cancer depends on the specific MMR gene that is 
mutated. MLH1 and MSH2 have been shown to have higher lifetime risks than MSH6 and 
PMS2.13,71 In a recent multicenter prospective observational study, the cumulative incidence of 
ovarian cancer was 11% for MLH1 pathogenic variant carriers, 17.4% for MSH2, 10.8% for MSH6, 
and 3% for PMS2.13 
Ovarian cancer is typically diagnosed between ages 42 and 49 for patients with Lynch 
syndrome.9,71,73,74 One study that examined data on more than 800 women from a Lynch syndrome 
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registry and cohort study calculated a median age of onset of 46 years for ovarian cancer; the range 
of age of onset was wide, with the youngest woman being 20 years old and the oldest being 75.9 
Tumor histology is most often endometroid, although serous carcinomas are also associated with 
Lynch syndrome.9,73,74 The survival rate of ovarian cancers related to Lynch syndrome is high—
likely in part due to the difference in tumor histology characteristics—with studies finding a 10-
year survival of 84-87%.13,73  
2.2.3 Other genes 
Pathogenic variants in other genes involved in homologous recombination have been 
identified to increase a woman’s risk of EOC. Recently identified genes include RAD51C, 
RAD51D, BRIP1, and PALB2.63,64,75-77 One study examined pedigrees from 480 families with a 
history of breast and ovarian cancer that had negative BRCA1/2 testing results. The researchers 
found that 1.3% of families had a pathogenic variant in RAD51C segregating with disease.76 
Another study examined 911 BRCA1/2-negative families with breast and ovarian cancer and found 
that 0.9% carried pathogenic variants in RAD51D. The relative risk of ovarian cancer for 
pathogenic variant carriers was estimated to be 6.3 times population risk, while the relative risk 
for breast cancer was 1.3 and not statistically significant.75 Pathogenic variants in BRIP1 increase 
risk mainly for high-grade serous EOC, although the specific risk is not currently well-understood. 
Older ages of diagnosis are also associated with BRIP1 pathogenic variants.63 One study found 
that certain frameshift BRIP1 pathogenic variants significantly increased the risk for ovarian 
cancer, while more common missense variants were not associated with increased risk.77 Finally, 
PALB2 pathogenic variants are known to confer breast cancer susceptibility, but more studies are 
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finding that ovarian cancer risk may be increased as well. Further research is needed to better 
determine the estimated ovarian cancer risk associated with pathogenic variants in this gene.63,65 
Massively parallel sequencing has identified other potential ovarian cancer susceptibility 
genes, but more studies are needed to fully understand their penetrance and risks. One study 
utilized this sequencing technology with 360 women with ovarian, fallopian tube, or peritoneal 
cancers and found germline pathogenic variants in 23% of them. 18% of pathogenic variants were 
in BRCA1/2, and the other 6% were in MSH6, RAD51C, BRIP1, PALB2, TP53, BARD1, CHEK2, 
MRE11A, NBN, and RAD50. At the time of this study, RAD51D had not been implicated in ovarian 
cancer predisposition and was therefore not included. All genes identified, with the exception of 
MSH6 and TP53, are involved in the homologous recombination pathway. Importantly, the women 
with MSH6 and TP53 germline pathogenic variants did not meet criteria for Lynch syndrome or 
Li-Fraumeni syndrome, respectively. 30% of women in the study had no family history of breast 
or ovarian cancer, again pointing to the need for testing without such a history.3 
2.3 Ovarian Cancer Genetic Testing 
In the field of cancer, genetic testing can be ordered for a variety of reasons. Regardless of 
whether an individual is affected, genetic testing can increase knowledge about personal and 
family cancer risks. It can provide an explanation for a personal or family history of cancer if a 
genetic pathogenic variant is found. For affected individuals, genetic testing can result in 
personalized treatment. Unaffected persons may benefit from enhanced surveillance or options for 
risk reduction. Sometimes, genetic testing can provide reassurance that there is likely not a single-
gene predisposition to cancer in the family. 
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2.3.1 Utility of ovarian cancer genetic testing 
For patients with ovarian cancer, genetic testing can inform prognosis and guide 
treatment.8,78-80 Tumor testing alone can provide this information, but given the high frequency of 
germline pathogenic variants in patients with EOC, it does not provide all needed information. 
Germline results must be delineated in addition to somatic results to provide the patient and their 
family with the most comprehensive medical information. BRCA1/2 testing was historically more 
commonly used, but with the advent of next-generation sequencing, multi-gene panel testing has 
become both feasible and necessary and has been utilized more frequently in recent years.17,81 
2.3.1.1 BRCA1/2: Management and Screening 
Primary treatment of ovarian cancer is typically platinum chemotherapy and surgery to 
remove the tumor, followed by maintenance therapy.7 A study comparing ovarian cancer outcomes 
in carriers of BRCA1/2 pathogenic variants with non-carriers found an improved prognosis and a 
better response to platinum-based chemotherapy.80 The presence or absence of a BRCA1/2 
pathogenic variant guides the selection of and provides information on the magnitude of benefit of 
maintenance therapy as well.7 Maintenance therapy is typically achieved through poly ADP-ribose 
polymerase (PARP) inhibitors, which prevent cancer cells from repairing their damaged DNA and 
can help to trigger apoptosis. Until recently, PARP inhibitors were only recommended for 
metastatic treatment of homologous recombination (HR) deficient tumors—such as a BRCA1/2 
mutated tumor—after at least three other lines of therapeutic therapy had been utilized.78 The 
PARP inhibitor Niraparib is now FDA-approved as first-line maintenance therapy after response 
to platinum-based chemotherapy for late-stage ovarian cancer, regardless of the HR status of the 
tumor. It is important to note, however, that the response to Niraparib was significantly better for 
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HR deficient tumors. For example, in the clinical trial, the median progression-free survival was 
21.9 months for HR deficient tumors compared to 13.8 months in the overall population; this value 
for the placebo group was 10.4 months.8 Knowledge of BRCA1/2 tumor status is therefore essential 
for treatment and prognosis purposes.  
As mentioned previously, tumor testing alone is not sufficient due to the high prevalence 
of germline pathogenic variants in patients with ovarian cancer.67 Identifying somatic mutations 
in the tumor provides information for treatment of the tumor only; identifying germline mutations 
present in the entire body provides information for screening and risk reduction of all cancers 
associated with the mutation. Unaffected relatives also greatly benefit from genetic testing for 
ovarian cancer susceptibility genes. If a pathogenic variant is identified in an affected relative, 
cascade testing permits the testing of blood relatives for the same variant to identify those at 
increased risk for EOC. As there are currently no effective screening methods, the main benefit of 
genetic testing lies in risk reduction.12,24 For women with pathogenic variants in BRCA1/2 who are 
unaffected with ovarian cancer, it is recommended that they undergo a risk-reducing salpingo-
oophorectomy once childbearing is completed, ideally between the ages of 35-40 for BRCA1 and 
between the ages of 40-45 for BRCA2. If there is an ovarian cancer diagnosis in the family prior 
to the recommended age for RRSO, then earlier prophylactic surgery should be discussed.4 
Although this procedure significantly reduces the risk of ovarian cancer,  and possibly breast 
cancer, it does incur some risks associated with early menopause, such as osteoporosis and heart 
disease.82,83  
There are guidelines in place for the additional cancer risks associated with BRCA1/2 
pathogenic variants as well. Note that while these recommendations are standard, they may or may 
not be indicated in patients with EOC, depending on their clinical picture. Breast cancer screening 
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begins at age 25 with an annual MRI. Beginning at age 30, a mammogram should occur annually 
with the MRI. The option of a risk-reducing bilateral mastectomy should be discussed. Pancreatic 
screening may also be justified, although data for its efficacy are limited.4 The American 
Gastroenterological Association currently recommends screening in individuals with pathogenic 
variants in BRCA1/2 only if there is a first degree relative with pancreatic cancer.84 
2.3.1.2 Mismatch repair genes: Management and Screening 
Women diagnosed ovarian cancer who have mismatch repair deficient (dMMR) tumors 
may have tailored therapy options. While there are not as many targeted therapy options for non-
BRCA1/2 pathogenic variants in ovarian cancer tumors, a growing body of evidence is suggesting 
that targeted therapy is warranted for dMMR tumors.85 Pembrolizumab is a specific 
immunotherapy, for example, that has been shown to have increased efficacy in dMMR ovarian 
cancer tumors. There are numerous clinical trials available for patients with dMMR tumors, and 
thus targeted therapies will likely become more widely available in the future. Patients with dMMR 
tumors have also been shown to have improved survival, making it a useful marker for prognosis.9 
For unaffected women with pathogenic variants in MLH1 and MSH2, risk-reducing RRSO is 
recommended; for individuals with pathogenic variants in PMS2, EPCAM, or MSH6, there is 
currently insufficient evidence to recommend RRSO.86 
 There are additional screening and management guidelines for germline MMR pathogenic 
variants, which may or may not be applicable to individuals affected with ovarian cancer. The two 
largest risks and most well-defined screening guidelines are for colon and endometrial cancer.13 
For men and women, colonoscopies should begin between the ages of 20 and 25 (or 2-5 years prior 
to the earliest colon cancer in the family, if earlier) and should be repeated every 1-2 years.86 Daily 
aspirin use has been shown to reduce colorectal cancer risk, although more data is needed in order 
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to determine an optimal dosage and duration of use.87 Pancreatic cancer screening is recommended 
only if an individual has an affected first-degree relative.84 Many women affected with ovarian 
cancer have a total abdominal hysterectomy in addition to oophorectomy, and thus have reduced 
their endometrial cancer risk by as much as possible. Unaffected women should be educated on 
symptoms of endometrial cancer. Screening via endometrial biopsy every 1-2 years can be 
considered starting at age 30-35.  A risk-reducing hysterectomy can be considered as well.86 
2.3.1.3 Other genes: Management and Screening 
Other moderate-risk pathogenic variants as previously described warrant additional 
screening, although guidelines are generally not as well-established. Affected women with 
pathogenic variants that result in homologous recombination deficiency have an improved 
response to maintenance therapy with PARP inhibitors.4,7 Clinical trials or other targeted therapies 
may become available for other genes and should be investigated when genetic test results are 
available. For unaffected women, RRSO should be considered between age 40-45 for women with 
a pathogenic variant in BRIP1 and 45-50 for RAD51C/D, or earlier if family history of early-onset 
ovarian cancer is present. Further studies are needed to establish whether or not RRSO is warranted 
for other moderate-risk genes. Women with a pathogenic variant in PALB2 can consider RSSO 
after menopause if there is a family history of ovarian cancer. They should begin annual breast 
mammograms with MRI at age 30 and should discuss the option of a bilateral risk-reducing 
mastectomy. For other genes, breast cancer surveillance should be based on family history.4  
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2.3.2 Factors that Influence Genetic Testing Decisions 
There are several factors that may predict whether a person decides to undergo genetic 
testing, but there is inconsistency from study to study regarding which factors are significant.88 
Some of these factors have changed as genetic testing methods and anti-discrimination laws have 
been updated. In older studies, predictors of BRCA1/2 genetic testing uptake included being 
Caucasian, older, and wealthier as well as having children, a family history of breast or ovarian 
cancer, and a higher level of knowledge about genetic testing.89-91 One study from 2011 noted that 
the ability to cure or reduce the risk of a disorder also appeared to be a strong predictor of genetic 
testing; 77% of individuals were theoretically willing to undergo testing for a curable condition, 
while only 50% of individuals were interested in testing for an incurable disorder.92 Studies within 
the past ten years have conflicting evidence as to whether or not age, race, and education level are 
predictors of genetic testing. However, relatively consistent predictors of testing uptake include 
having a personal or family history of cancer, having a higher income, being more knowledgeable 
about genetics, and perceiving more benefits to the test than risks.88,93-95 A recent study also found 
that having discussed genetic testing with a surgeon was a strong predictor of genetic testing in 
newly diagnosed breast cancer patients.96   
Several studies have attempted to elucidate specific reasons why unaffected individuals 
decline genetic testing. One study looking only at genetic testing for BRCA1 in unaffected 
individuals from HBOC families noted that individuals were more likely to request testing if they 
had a higher socioeconomic status and adequate health insurance. This study took place in 1996, 
prior to the passing of the Genetic Information Non-Discrimination Act (GINA), so many 
individuals cited a fear of discrimination from employers or health insurance as the reason they 
declined testing.91 Another study from 2003 with 13 women at risk of carrying a pathogenic variant 
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in BRCA1/2 found that being satisfied with participating in a surveillance program and being 
emotionally unprepared to cope with testing results were also reasons that testing was declined. 
Additionally, women who had a higher reluctance toward undergoing prophylactic surgery were 
less likely to move forward with genetic testing compared to women who were more comfortable 
with surgical intervention.97 Newer studies highlight additional reasons why patients opt out of 
genetic testing, including distrust in genetic information, perception of more risks than benefits, 
and significant financial barriers.98,99 One retrospective chart review from 2018 found that 267 of 
1082 individuals who met NCCN criteria for BRCA1/2 analysis did not receive genetic testing. 
However, only 22% of these individuals were disinterested in testing. 40% were advised to gather 
additional information from relatives before testing, and 38% desired testing but were prohibited 
by the cost.98 
In all aspects of medical care, health literacy plays an important role; this is the ability of 
a person to get the health-related information they need, understand it, and utilize it appropriately 
to make medical decisions. All health care professionals have a vital role in understanding how 
health literacy influences the care that patients receive. When it comes to genetic testing, limited 
health literacy has been consistently shown to be associated with lower genetic health knowledge. 
One study examined how genetic health literacy plays a role in understanding genetic testing; the 
results indicated that patients’ understanding of the utility of genetic testing is positively correlated 
with genetic health literacy.100 Another study interestingly noted that patients with low health 
literacy had a greater perceived importance of genetic information but a lower perceived 
importance of family health history information, suggesting a disconnect in their understanding of 
genetics and genetic testing.101 It is therefore essential that health care providers be aware of their 
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patient’s level of health literacy in order to appropriately communicate information and create 
equitable health care for all patients. 
2.3.3 Psychological Impact of Genetic Testing Results 
Previous studies have generally shown favorable psychosocial outcomes after genetic 
testing, with a slight increase in anxiety immediately after results are disclosed, followed by a 
return to pre-testing anxiety levels.102,103 A comprehensive review by Hirschberg et al. found that 
both men and women who receive genetic testing for hereditary cancer syndromes experience no 
clinically significant long-term distress. Any psychological distress that does arise during the 
testing process appears to decrease over the course of the first year after testing. Individuals tested 
positive for a pathogenic variant in a cancer predisposition gene who continue to have higher levels 
of distress after testing tend to have a higher level of baseline distress, a history of depression 
and/or psychotropic drug use, an elevated risk perception, complicated grief or unresolved loss, 
especially if they lost a relative due to hereditary cancer. Additionally, individuals with children 
were more likely to have long-term distress.104 Being aware of these risk factors can facilitate the 
counseling process and can better prepare patients for their testing results. 
2.4 Alternative Service Delivery Models 
The growing demand for genetics services, combined with the deficit in genetics health 
care professionals, has led to a call for alternative service delivery models.15,105 The most recent 
practice analysis conducted by the American Board of Genetic Counselors (ABGC) found that 
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only 77.3% of certified genetic counselors are currently working in clinic, and 40.6% are working 
in cancer.106 More studies are necessary to clarify how many cancer genetic counselors are needed 
to meet current demand.  Geographical barriers are a major access concern; a study in California 
found that genetics providers are concentrated in major metropolitan areas, and on average patients 
travel approximately 80 miles to access these services.15 To increase patient access, many cancer 
genetics providers have incorporated alternative service delivery models into their practice such 
as telephone, telemedicine, pre-recorded videos, or group genetic counseling. These models 
mitigate issues with travel distance and are generally more convenient for both the counselor and 
the patients, but issues with billing or reimbursement, equipment setup, and internet access, as well 
as the inability to physically see the patient hinder some efforts.107  
Studies have shown that alternative care delivery models result in an increase in genetics 
knowledge and access to services, although the effects on risk perception and possible lingering 
misconceptions warrant further study.108-111 The Cancer Risk Education Intervention Tool 
(CREdIT) was designed to facilitate pre-counseling education for low literacy women who are at 
an increased risk for breast and ovarian cancer. Participants’ general genetics knowledge improved 
after viewing the CREdIT slides, but changes in risk perception varied between participants—
sometimes inappropriately increasing or decreasing. Additionally, some misconceptions remained 
after viewing the content; one woman still thought that she inherited her cancer predisposition 
from her niece, for example.109  
2.4.1 Cancer Genetic Testing by Non-Genetic Health Professionals 
With the increase in interest in genetics services, many non-genetic health professionals 
(NGHPs) are ordering genetic testing themselves instead of referring patients to a genetics 
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provider. A recent survey investigating the attitudes, knowledge, and skills of NGHPs with regards 
to hereditary cancer testing found that these providers generally have positive views about their 
communication skills and are confident in their ability to take a family history and order genetic 
testing. The majority of providers responded that they discussed the benefits and limitations of 
close cancer surveillance (95%) and prophylactic surgery (89%), discussing results with family 
members (91%), and confidentiality (89%). Importantly, however, only 71% of providers thought 
it was their responsibility to manage emotions; 68% felt confident in their ability to interpret 
variants, and 55% had received formal training on communicating hereditary information.112 Other 
studies have noted that an increase in knowledge corresponds to an increase in the confidence of 
the provider to deliver genetics services, and many providers asked for more formal training in 
genetics.113-115 A study by the American Society of Breast Surgeons found that the majority of 
breast surgeons provided genetic testing and counseling, created 3-generation pedigrees and 
provided pre- and post-test counseling. Still, 11.8% of respondents did not feel confident in their 
ability to provide counseling and desired more educational support in genetics.114  It thus appears 
that NGHPs are willing and eager to provide genetics services, but more educational opportunities 
to increase their knowledge of genetics may be necessary to improve confidence in all aspects of 
the genetic testing process. 
2.4.1.1 Knowledge Gaps and Educational Needs 
One method to mitigate this issue is to provide more formal education in topics related to 
hereditary cancer genetics and genetic testing so that providers can better understand this process 
and identify which patients require a referral. A plethora of studies have examined the current level 
of genetics knowledge in NGHPs and the effects of educational programs. Genomic literacy and 
confidence appear to differ greatly between practice groups, provider specialty, and years of 
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practice. For example, OB-GYNs and specialists (e.g. surgeons and oncologists) generally have 
greater genetics knowledge and confidence compared to primary care physicians.113,116,117 
Common knowledge gaps include the inability to recognize paternal inheritance of HBOC, the 
need for comprehensive rearrangement testing in high-risk women, and appropriate testing options 
for a VUS result.118,119 One study surveyed providers in Florida who order BRCA1/2 testing and 
assessed the educational needs and preferences among this group; responses from mostly 
physicians and nurse practitioners indicated that in-person training was most strongly preferred. 
Minimal time off work and continuing education credits were also strong motivators to participate 
in formal education training.120 Other commonly reported preferred educational methods include 
multi-modal genetics courses that combine distance learning with interdisciplinary in-person 
training, seminars detailing clinical genetics services referral pathways, electronic referral 
guidelines, and example case scenarios.116,121,122 A study conducted by the City of Hope 
demonstrated that a targeted outreach program among community-based clinicians resulted in a 
40% increase in cancer genetics knowledge on average. 77% of participants felt that they could 
use the course information and materials to better counsel and refer patients for hereditary cancer 
risk assessment.123 Various professional societies and academic institutions currently offer 
seminars, workshops, and web-based curriculum and resources to help educate providers.124 
2.4.1.2 Motivations for and barriers to cancer genetics referrals 
Although education programs aim to increase genetic literacy and knowledge, they are also 
intended to increase appropriate referrals to hereditary cancer genetics services. A survey of 
NGHPs indicated that common reasons for referral include eligibility based on the patient’s 
personal or family history, the need for enhanced risk assessment, improved medical management, 
concern for family members, and patient request. Major barriers to referral included a lack of 
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knowledge about a cancer genetics program and limited awareness of improved insurance 
coverage and anti-discrimination legislation.125 Another study that surveyed gastroenterologists 
and colorectal surgeons found that 82.7% had referred a patient to cancer genetic counseling. The 
majority of those surveyed were able to correctly identify which patients were at a “much higher” 
risk to develop colorectal cancer than the general population; fewer were able to identify those at 
“somewhat higher” risk than the general population. Risk categories were based off the American 
Gastroenterological Association’s criteria for high, moderate, and average risk to develop 
colorectal cancer. The survey identified barriers to referral including insurance coverage issues 
and discrimination fears, as well as a lack of clear guidelines from professional organizations. 
Similar to previously mentioned studies, physicians were more confident ordering testing than 
interpreting the results or providing emotional support.126  
2.4.1.3 Adverse effects of incorrect testing and non-referrals 
Many studies illustrate the negative effects that occur when testing is ordered incorrectly, 
or when appropriate referrals are not made. A national case series examined patterns from 21 cases 
submitted to the National Society of Genetic Counselors Cancer Special Interest Group that 
exhibited adverse outcomes of testing by NGHPs. Major patterns noted were: the wrong genetic 
test was ordered (e.g. BRCA1/2 analysis instead of MMR genes or full-sequencing when a familial 
pathogenic variant was known), the results were mis-interpreted (e.g. a VUS was counseled as if 
pathogenic or incorrectly considering a patient to have a “true negative” result), and inadequate 
genetic counseling was given.127 Negative outcomes of errors in genetic testing and result 
interpretation include unnecessary prophylactic surgery, unnecessary testing, psychosocial 
distress, false reassurance, and increased cost to insurance companies and patients.127,128 Provider 
education could lead to improved availability of services and more appropriate care. 
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2.4.2 Oncologist-Led Genetic Testing for Epithelial Ovarian Cancer Patients 
Data from the National Health Interview Survey (NHIS) and a recent study indicated that 
only a third of individuals with a history of ovarian cancer have undergone genetic testing, despite 
current NCCN guidelines that all these women should receive genetic testing.7,17,93 Only 15% of 
patients with ovarian cancer had even discussed genetic testing with a healthcare provider.93 An 
increase in public awareness, targeted at providers and women with ovarian cancer, may help to 
increase utilization of genetics services.90,93 Professional organizations like the American College 
of Obstetricians and Gynecologists (ACOG), American Society of Clinical Oncology (ASCO), 
and Society of Gynecologic Oncologists (SGO) have published recommendations and guidelines 
that support germline and somatic genetic testing for epithelial ovarian cancer patients at the time 
of diagnosis; they state informed consent is required, including a discussion of the benefits, 
limitations, and implications of genetic testing results.5,6,129,130 SGO specifically recommends that 
patients begin with genetic counseling to discuss testing options, but they also acknowledge that 
if these services are not available from a genetic counselor, it is appropriate to receive counseling 
from a provider trained in cancer genetic counseling.6  
A streamlined BRCA1/2 genetic testing pathway for ovarian cancer patients has been 
proposed and studied in recent years. Colombo et al. published the results of a study entitled 
Evaluating a Streamlined Onco-genetic BRCA Testing and Counseling Model Among Patients 
with Ovarian Cancer (ENGAGE). In this study, a clinical team of oncologists and oncology nurses 
received training on BRCA1/2 testing and genetic counseling techniques. Pre-test counseling was 
provided by this team, although patients could elect to have counseling from a genetic counselor 
or geneticist prior to testing if desired. Results were disclosed by the clinical team, and patients 
with a positive result were recommended to undergo further genetic counseling with a genetic 
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counselor or geneticist. The results of the study were favorable, with a median turnaround time of 
4.1 weeks in the United States. Patient satisfaction was 99%, and 80% of oncologists agreed that 
the process worked well and was efficient. However, only 50% of genetic counselors and 
geneticists agreed that patients received accurate BRCA1/2 testing information in the pre-test 
counseling session, suggesting that the process still requires some fine-tuning.19  
Barriers to implementing this type of streamlined pathway have been reported, including a 
limited number of providers that were appropriately trained, time constraints, insufficient health 
insurance, fear of discrimination, and issues with family communication.124,131 Issues that arise 
once the pathway has been implemented include difficulty interpreting a VUS result and lack of 
patient awareness of result implications for their own treatment.19,132 Pre-test counseling requires 
improvements to better educate patients, and referrals to a genetics provider are likely warranted 
for not only positive results, but also VUS results and a negative result for a patient with a family 
history.18 Still, other studies have shown comparable results with quick turnaround time, high 
patient satisfaction, high rates of genetic counseling appointment attendance, and appropriate 
changes in treatment based on genetic testing results.18,131,133,134 Patients were satisfied with the 
timing of testing and did not appear to be overwhelmed with the additional testing at the time of 





Every year, nearly 300,000 women receive a diagnosis of ovarian cancer across the world. 
As the 5th leading cause of cancer death in women, the diagnosis is often devastating.20 Genetic 
predispositions to ovarian cancer have been identified and are thought to contribute to 20-25% of 
cases.2 Hereditary Breast and Ovarian Cancer syndrome (HBOC), Lynch syndrome, and 
pathogenic variants in moderate-risk genes have all been demonstrated to increase a woman’s 
lifetime risk of developing ovarian cancer.3,9,67,72  
Due to the high frequency of germline pathogenic variants, current NCCN guidelines 
advise that all women diagnosed with epithelial ovarian cancer (EOC) be offered germline genetic 
testing.7 In spite of this, only about 35% of women with this diagnosis have undergone genetic 
testing.17 Knowledge of a germline pathogenic variant in an affected individual can inform 
prognosis, guide treatment, and clarify the need for management of other cancer risk. Studies show 
that women with BRCA1/2 pathogenic variants have an improved prognosis and a better response 
to platinum-based chemotherapy and PARP inhibitors.8,78,80 These women may also benefit from 
additional cancer screening due to an increased risk of breast cancer, depending on their clinical 
status.14,70 Similarly, women with germline pathogenic variants in a Lynch-syndrome related gene 
have a higher survival rate, and some treatment options such as Pembrolizumab are targeted for 
mismatch-repair deficient tumors.9,85 Surveillance with frequent colonoscopies and endometrial 
biopsies might also be indicated for colon and endometrial cancer risk management.13  
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Tumor testing alone can provide information to determine indications for targeted 
treatment options, but it cannot differentiate between germline and somatic variants. Identification 
of a germline pathogenic variant provides information on additional cancer risks, and it helps 
facilitate testing for at-risk family members. As such, tumor testing alone is not sufficient for 
women diagnosed with ovarian cancer. Germline genetic testing, or tumor testing followed by 
germline testing if there are results suspicious for a germline pathogenic variant, is necessary to 
provide comprehensive risk assessments to the patient and their families.  
While the demand for genetic services has increased, there is a deficit in genetics health 
professionals.15,105 This has resulted in a call for alternative genetics service delivery models. Many 
non-genetics health professionals (NGHPs) are increasingly ordering genetic testing themselves, 
especially within the realm of hereditary cancer testing. Studies of oncologist-led testing pathways 
have been favorable so far, with quick turnaround times and high levels of patient and provider 
satisfaction.19,133,134 However, knowledge gaps and barriers to cancer genetics referrals after testing 
is completed persist and must be addressed for this service model to provide appropriate care. A 
recent study found that most NGHPs’ self-reported proficiency discussing the benefits and 
limitations to close surveillance and risk-reducing surgery, importance of delineating information 
to family members, and confidentiality of results. However, only 68% felt confident in interpreting 
all variants, and 55% had never received formal training in communicating this information.112 
This theme has been replicated in other studies, as the American Society of Breast Surgeons 
reported that most providers were ordering genetic testing and were counseling patients on results, 
but 11.8% of respondents did not feel confident in their counseling abilities and desired more 
educational support in genetics.114 Targeted outreach programs have been successful in the past in 
improving genetics knowledge, appropriate referrals, and counseling abilities.123 Errors in genetics 
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service delivery can have severe negative outcomes including unnecessary prophylactic surgery, 
inappropriate testing, psychological distress, false reassurance, and increased cost to insurance 
companies and patients.127,128  
The goal of this study was to evaluate the current genetic testing practices of oncology 
providers for patients with epithelial ovarian cancer. Data surrounding the genetic testing practices 
of gynecologic oncologists are limited, and these individuals are central healthcare providers for 
women diagnosed with ovarian cancer. This study will help to elucidate how and when 
gynecologic oncologists are ordering genetic testing and referring patients to genetics services, 
and it could help highlight any barriers that currently exist. It will also assess provider confidence 
with different aspects of cancer genetics services to identify areas that may require educational 
outreach. Addressing these issues will facilitate access to genetic testing services for all patients 
with ovarian cancer and their families. 
3.2 Methods 
3.2.1 Study Population 
A survey was sent to full and associate members of the Society of Gynecologic Oncology, 
a professional society comprised of gynecologic oncologists, researchers, medical oncologists, 
physician assistants, nurse practitioners, registered nurses, fellows, residents, students, patients, 
and caregivers. As healthcare systems differ vastly by country, only members who practice in the 
United States were recruited. Participants were deemed eligible if they are currently in clinical 
practice or have been in clinical practice within the past year.  
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3.2.2 Survey Development 
Prior to survey distribution, exempt IRB approval was obtained from the University of 
Pittsburgh (Appendix A). The survey was developed utilizing the Qualtrics Survey System, which 
was accessible through the University of Pittsburgh license. The survey collected information on 
participant demographics, genetic testing and referral practices, and confidence with different 
aspects of the genetic testing process (Appendix B). It was estimated to take approximately 15 
minutes to complete. Demographic information recorded included current job title, primary area 
of medical practice, location (urban/suburban/rural), practice setting, years of experience, age, 
gender, and ethnicity. Genetic testing questions inquired about ordering frequency, timing, type of 
test (e.g., multi-gene panel vs. BRCA1/2 analysis only), barriers to testing, and how often results 
guide treatment decisions. Certain survey questions permitted multiple responses to be selected. 
Questions about referrals to genetics services similarly asked about frequency, timing, and barriers.  
Several potential barriers to ordering genetic testing were asked in the survey, including 
patient disinterest, insurance coverage or discrimination concerns, lack of effect on medical 
management, lack of necessity, and confusion. A list of barriers to making cancer genetics referrals 
was provided for the respondents to select from, including patient disinterest, services already 
provided, insurance coverage or discrimination concerns, burden of additional appointments, lack 
of services in region, and confusion or lack of knowledge about services. Finally, a group of 
questions asked about education or training in genetics and confidence in: taking a 3-generation 
family history, ordering genetic testing, interpreting all possible results, counseling a patient on 
the meaning of the result, and deciding which patients should be referred to cancer genetics 
services. Respondents completed the survey online. Due to time constraints, the survey was not 
piloted. 
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3.2.3 Recruitment and Survey Distribution 
An e-mail was sent out to invite members of SGO to participate in the research survey on 
December 14th, 2020. The recruitment e-mail explained the goals of the study, pointed out potential 
risks and benefits to taking the survey, provided researcher contact information, and had a link to 
the survey (Appendix C). The survey was open for a total of six weeks and closed on January 22nd, 
2021. Two reminder e-mails were sent out with two weeks and one week remaining. An informed 
consent paragraph appeared before any survey questions could be viewed and required the 
participant to acknowledge to continue (Appendix B). Survey completion was used as proof of 
informed consent. Respondents that completed less than half the questions were not included, as 
not all questions necessary for analysis were answered (i.e., missing information on frequency of 
referrals, provider confidence, and demographic information). 
3.2.4 Data Analysis 
Descriptive statistics were performed and bar graph data visualizations were created using 
Qualtrics for demographic information, testing and referral practices and barriers, and provider 
confidence. Cross tabulations were calculated between provider testing practice and both use of 
genetic testing results to guide treatment and frequency of referrals made. Statistical analysis was 
performed using STATA statistical software. Fisher’s exact test was utilized to determine if there 
was a significant association between provider testing practice and confidence levels with different 
aspects of cancer genetics services and referrals. P-values were considered significant if they were 
less than 0.05. All outputs from statistical analysis can be found in Appendix D. 
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3.3 Results 
3.3.1 Demographic Information 
The survey was sent to 1,444 members of SGO who are full or associate members currently 
residing in the United States. A total of 186 responses were received, therefore giving the study a 
12.9% response rate. Twelve responses were excluded because less than half of the questions were 
answered. Four additional responses from individuals who are not currently in clinical practice 
were also excluded. Hence, 170 responses were included in the analysis.  
Almost 82% of respondents were gynecologist oncologists (Table 3), and nurse 
practitioners comprised the next largest group (10.6%). Thirty-three percent of respondents had 
10-19 years of experience in patient care. Approximately 25% of respondents had 0-9 years of 
experience, and another 25% had 20-29 years. 17% of respondents had 30 or more years of 
experience. The majority (95.3%) of respondents worked primarily in gynecology/obstetrics or 
gynecologic oncology. Most respondents were white (84.7%), non-Hispanic (94.1%), and between 
the ages 30-69 (97.1%), and slightly more respondents were female (63.5%) than male. Individuals 
were asked two questions about practice type and location. Note that total percentages can be 
higher than 100 due to the ability to select multiple responses. The majority of respondents (53.5%) 
worked at an academic center at least some of the time and 36.5% of respondents were hospital 
based. More individuals reported to be part of a group practice (20%) than a private practice 
(8.8%). Most respondents worked in an urban setting (66.5%) at least some of the time, followed 
by suburban (40.6%) and then rural (7.1%). Individuals that selected “Other” specified working at 
referral centers and in the military (Table 3). Patients with epithelial ovarian cancer made up less 
than half of all patients seen in clinical practice for 90% of providers.  
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Table 3. Respondent Demographic Information 
Current job title % (n) 
Gynecologic oncologist 81.8% (139) 
Medical oncologist 2.4% (4) 
Surgical oncologist 0% (0) 
Nurse practitioner 10.6% (18) 
Physician assistant 3.5% (6) 
Registered nurse 0.6% (1) 
Other 1.2% (2) 
Years of experience in patient care   
0 - 9 27.1% (46) 
10 - 19 33.5% (57) 
20 - 29  22.4% (38) 
30 or more 17.1% (29) 
Primary area of medical practice  
Gynecology/obstetrics 60.6% (103) 
Other (Gynecologic Oncology) 34.7% (59) 
Internal medicine 0.6% (1) 
Family practice 0% (0) 
Other 3.5% (6) 
Age  
29 or younger 0.6% (1) 
30 - 49  57.1% (97) 
50 - 69  40.0% (68) 
70 years or older 2.4% (4) 
Gender  
Female 63.5% (108) 
Male 36.5% (62) 
Ethnicity (select all that apply)  
American Indian or Alaskan Native 0% (0) 
Asian 6.5% (11) 
Black or African-American 5.3% (9) 
White 84.7% (144) 
Other 1.8% (3) 
Hispanic, LatinX, or Spanish origin  
Yes 2.9% (5) 
No 94.1% (160) 
Location (select all that apply)  
Rural 7.1% (12) 
Suburban 40.6% (69) 
Urban 66.5% (113) 
Other 3.5% (6) 
Practice setting (select all that apply)  
Private practice 8.8% (15) 
Group practice 20.0% (34) 
Hospital based 36.5% (62) 
Academic center 53.5% (91) 
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3.3.2 Ordering, Treatment, and Referral Practices 
The majority (85%) of respondents always ordered genetic testing for patients with EOC 
(Table 4). The frequency that providers used genetic testing results to guide treatment and referred 
patients to cancer genetics was examined separately based on how often they ordered genetic 
testing. Of providers who always ordered genetic testing, about 30% also always used genetic 
testing results to guide treatment. 60% of these providers always referred patients to cancer 
genetics services. Of providers who often or sometimes ordered genetic testing, 23.8% always 
used the results to guide treatment, and a third always referred patients to cancer genetics. Only 
four providers responded that they never ordered their own genetic testing; all of these individuals 
always referred patients to cancer genetics.  
 
Table 4. Treatment and Referral Tendencies by Testing Practice 
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Regarding the timing of testing, 64.5% of respondents indicated that they ordered testing 
at diagnosis (Figure 1). 37.3% of providers ordered before starting chemotherapy, and 34.3% 
ordered after beginning chemotherapy. Other responses included when a patient relapsed, after 
completion of chemotherapy, or after surgery has been performed. 
 
Figure 1. Percentage of providers who ordered genetic testing at indicated times in patient treatment 
Respondents were also asked to indicate the types of testing that they had ordered for 
patients with EOC in the past year and were permitted to select multiple types of testing. Panel 
testing was performed by 95.8% of providers (Figure 2). The second most frequently selected type 
of testing (44.0%) was somatic testing with reported germline mutations, followed by somatic 
testing without reported germline mutations (30.1%). Only 13.9% of providers indicated that they 
performed BRCA1/2 analysis alone in the past year. Other responses specified that test selection is 
deferred to genetic counselors. 
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Figure 2. Percentage of providers who ordered indicated type of genetic testing 
The majority of respondents (53.6%) felt that none of the potential barriers listed prevented 
or hindered them from ordering genetic testing. The most commonly cited barriers to testing were 
patient disinterest (30.4%) and insurance coverage concerns (13.7%). Other responses (9.5%) 
specified long wait times for genetic counseling appointments, the financial confusion that testing 
causes patients, and a lack of patient interest to share information with family. Three of the four 
providers who never ordered genetic testing clarified that genetic counselors are consulted to order 
testing based on the patient’s personal history and their family history. No providers felt that 
genetic testing was unnecessary or were confused by genetic testing. 
Providers were asked to select the timing at which they referred patients with EOC to 
cancer genetics services in the past year. About half of providers referred patients before genetic 
testing for pre-test counseling or at diagnosis (Figure 3). Almost 25% of providers referred patients 
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after ordering testing if there was a positive result; 14.3% referred patients after ordering testing if 
the result was unclear. 3.1% of providers refer after testing if there is a negative result. Other 
responses included after somatic testing if a germline mutation is suspected, when a result is in a 
gene the provider is not familiar with, when family history warrants further evaluation, or upon 
patient request. 
 
Figure 3. Percentage of providers who referred patients to cancer genetics services at indicated times in 
patient treatment 
40% of providers did not feel that any of the listed barriers prevented or hindered them 
from referring a patient to cancer genetics services. A third of providers felt that patient disinterest 
was a barrier. 17.3% of providers felt that they provided the necessary services to the patient. 
Insurance coverage and burdening patients with additional appointments were less commonly 
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indicated as barriers.  Lack of cancer genetics services in the area was selected by 5% of providers. 
No respondents cited confusion about cancer genetics services as a barrier to referrals.   
3.3.3 Genetics Education 
Providers were asked to indicate if they had attended educational courses, events, and 
programs. The most commonly reported form of genetics education (71.2%) was talks at 
conferences focused on genetics. Continuing education events, genetics courses in medical school, 
and webinars were the next most commonly selected responses. About 10% of respondents did not 
have experience with any of the genetics education forms listed. Other forms of genetics education 
specified included a Masters or PhD in Genetics, research, on-the-job training in genetics, years 
of experience, and the City of Hope course. 
3.3.4 Provider Confidence 
Five questions were posed to assess providers’ confidence level with various aspects of 
cancer genetics services: taking a detailed family history, ordering genetic testing, interpreting 
results, counseling a patient on the meaning of results, and making a referral to cancer genetics 
services. Provider confidence levels were broken down and analyzed by testing practices. The 
majority of those who always ordered genetic testing were very confident in each part of the testing 
process; however, only 43.4% of these providers were very confident in their ability to take a 
detailed family history, and 13.1% described themselves as not confident. Similarly, almost 50% 
of those who often or sometimes ordered testing were only somewhat confident with this process. 
The majority of these providers were somewhat or not confident with aspects of the testing process, 
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except when it comes to knowing which patients to refer. 86% of providers who sometimes or 
often order testing are very confident in their ability to identify patients that warrant a referral. 
Only four providers never ordered testing, and their confidence levels varied. Three of the four 
providers were not confident with their ability to order testing, and all four were very confident in 
their ability to appropriately make referrals. 
Fisher’s exact test determined there was no statistically significant difference between 
providers with different testing practices in regard to their confidence taking a detailed family 
history and deciding which patients to refer to cancer genetics. However, there was a significant 
difference between providers in confidence ordering testing as well as interpreting and counseling 
a patient on the meaning of genetic test results. Providers who always ordered genetic testing 
tended to describe themselves as very confident, while many providers who often or sometimes 
ordered testing tended to be somewhat confident (Table 5). 
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Table 5. Provider Confidence with Aspects of Cancer Genetics Services by Testing Practices  
Confidence 
Level 
I always ordered 
genetic testing 
I often/sometimes 
ordered genetic testing 
I never ordered 
genetic testing 
p 





























































































































3.4.1 Current Genetic Testing and Referral Practices by Oncology Providers 
Current NCCN guidelines recommend that all patients with epithelial ovarian cancer 
(EOC) be offered germline genetic testing.4,7 The first goal of this study was to gain an 
understanding of how oncology providers are currently ordering and utilizing genetic testing 
results in their practice for patients with EOC. Results from this study are encouraging, 
demonstrating that the overwhelming majority (85%) of oncology providers always order genetic 
testing for patients with EOC. Providers most often order genetic testing at diagnosis and typically 
order multi-gene panel or somatic testing. Many providers did not feel that listed barriers to testing 
and referrals applied to them, although patient disinterest and insurance coverage issues were 
sometimes indicated. 
Recent literature has found that only about 35% of patients with ovarian cancer have 
received genetic testing in spite of guidelines recommending testing for all of these patients.17 
However, this study found that 85% of gynecologic oncologists always ordered testing for patients 
with EOC in the past year. With such a high rate of providers always ordering testing, one would 
expect a higher percentage of patients to have received testing. There are several possible 
explanations for this discrepancy. First, this study focused on provider testing practice within the 
past year across the country. The study that estimated 35% of ovarian cancer patients to have 
received genetic testing collected data for women in California and Georgia only from 2012-2019. 
Additionally, the recent emergence of companion testing may also be increasing the proportion of 
patients with ovarian cancer who have received testing; Myriad Genetics launched their version of 
companion testing in 2014, for example. Therefore, better awareness of guidelines and improved 
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options for testing may have increased testing rates in very recent years. Additionally, providers 
might be ordering genetic testing for their patients with EOC, but genetic testing may not always 
be completed. Disease-related burden or patient disinterest could be preventing patients from going 
through with the testing, despite the order being in place. About 30% of providers listed patient 
disinterest as a barrier to testing, so it is possible that this is contributing to the discrepancy in 
ordering versus testing rates. 
The high prevalence of multi-gene testing found in this study is in concordance with other 
recent studies.17,95 The utility of multi-gene panel testing is well-established, as it can detect more 
pathogenic variants in clinically actionable genes than BRCA1/2 testing alone.81,95 Interestingly, a 
third of providers ordered somatic testing without reported germline mutations despite the high 
prevalence of germline pathogenic variants in patients with EOC.2,67 It is possible that patients 
were not interested in germline testing. Providers may perform follow-up germline testing if there 
is a somatic result that is suspicious for being germline or refer individuals with suspicious tumor 
test results to cancer genetics professionals. Additionally, current ASCO guidelines recommend 
that women with EOC with negative germline testing should have somatic testing.5 It is therefore 
also possible that providers ordered somatic testing as a follow-up test to negative germline testing. 
Because this survey only asked providers to list all types of testing they have ordered within the 
last year, further research is needed to clarify the context in which somatic testing is being ordered. 
In this study, testing at diagnosis was the most commonly reported timing of testing, in 
compliance with current guidelines. ASCO guidelines recommend germline genetic testing at the 
diagnosis of EOC in order to determine whether therapy with PARP inhibitors is indicated and to 
make decisions regarding neoadjuvant chemotherapy.5 Interestingly, the majority of providers—
regardless of their testing practice—indicated that they often or sometimes use test results to guide 
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treatment. However, both positive and negative genetic test results are informative for treatment 
and prognosis. Negative genetic test results can predict response to therapies and rule out the use 
of certain tailored therapies.7,8,78 Perhaps providers do not consider negative genetic test results to 
be informative for treatment purposes as no tailored therapies are available to wild-type patients. 
Further research is needed to investigate the situations in which providers do not use genetic test 
results to guide treatment. Testing was also ordered before or after beginning chemotherapy by 
about a third of survey respondents. The survey did not probe further into why testing was ordered 
at the indicated times, but there are many possible explanations. The patient may not have been 
seen by the provider until this stage in their treatment, or there could have been delays in being 
able to proceed with testing. A frequently mentioned “other” response to testing barriers was long 
wait times for genetic counseling appointments. Only four respondents indicated that genetic 
counselors handle all genetic testing for patients EOC.  This further supports the notion that an 
alternative service pathway for patients with EOC to undergo genetic testing is needed to improve 
access, as many other studies have found that there are not enough cancer genetics providers to 
meet patient needs.15,105,106  
The majority of providers that always ordered genetic testing for patients with EOC also 
always referred these patients to cancer genetics services, while those who ordered testing less 
often tended to refer patients less frequently. One possible interpretation of this trend is that 
providers who order their own testing have a greater knowledge of genetics and are more likely to 
recognize their limitations in providing all necessary services surrounding genetic testing, such as 
coordinating testing for family members and addressing patient emotions. This would be in line 
with other studies which have found that providers who have a greater familiarly and knowledge 
in genetics have higher rates of referrals.117,122,126 This study did not examine the reasons why these 
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providers were making referrals to genetics services. Apart from patient request or eligibility, 
commonly described motivations for referrals in current literature are to enhance risk assessment, 
improve medical management, and address concern for family members.125 Additionally, recent 
studies have found that many non-genetics healthcare professionals experience difficulty 
managing patient emotions and providing support.112,126 When asked about barriers to referrals, 
only 20% of providers surveyed responded that they provided all the needed services to the 
patients. Therefore, one explanation for the high rate of referrals among providers who order their 
own testing is that they recognize the benefits of genetic counseling and the additional services 
that can be provided by genetics professionals.   
3.4.2 Types of Genetics Education 
The most common forms of genetics education that respondents reported to have received 
were talks at conferences about genetics, Continuing Education events, and webinars. These 
platforms, while not formal training in genetics, have been frequently utilized by providers in the 
past and have been shown to increase genetics knowledge in previous studies.123,124 Some 
providers specified that multiple years of experience in their career supplied their genetics training. 
Providers with multiple years of experience should still be encouraged to improve their knowledge 
in genetics due to the rapidly evolving nature of the field.117 Educational sessions should continue 
to be offered in a variety of platforms to ensure accessibility.114,120 
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3.4.3 Confidence Levels of Oncology Providers with Genetic Testing Process 
Overall, providers were most confident in deciding which patients to refer to cancer 
genetics services and were least confident in taking a detailed, 3-generation family history. 
Confidence levels with these aspects of genetics did not significantly differ between providers with 
different testing practices. Previous studies have suggested that non-genetics healthcare providers 
are proficient at identifying high-risk patient that require referrals, but they tend to be less adept at 
identifying moderate or low risk patients.118,126 While high confidence levels for referring patients 
is reassuring, this study did not assess provider knowledge with or appropriateness of referrals 
being made. It is important that future studies ensure that appropriate referrals are being made for 
all patients. Confidence levels for obtaining a family history were slightly lower than expected; 
less than half of respondents felt very confident performing this task. One recent study found that 
91% of non-genetics healthcare providers felt confident taking a cancer genetics family history, 
and a survey of breast surgeons found that 90% of respondents were willing and able to take 3-
generation pedigrees for patients.112,114 Further research can determine what providers are 
struggling with when taking a family history. 
Finally, provider confidence with ordering testing, interpreting all possible results, and 
counseling the patients on the meaning of the results significantly differed between providers with 
different testing practices. Providers who always ordered their own genetic tests tended to label 
themselves as “very confident” in these tasks, while providers who ordered their own tests only 
often or sometimes labeled themselves “somewhat confident.” Many studies have demonstrated 
that the more confident a provider is with aspects of genetics services, the more likely they are to 
deliver those services themselves.112-114,125,126 These results are therefore not surprising and are in 
agreement with current literature. Recent studies have also shown that many providers struggle 
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with appropriately interpreting a variant of uncertain significance, negative results in the context 
of a strong family history, and results in less well-studied genes.18,19,62,112,127 These issues may be 
playing a role in provider confidence, but ultimately future studies are required to tease out why 
providers who order their own genetic testing less frequently tend to be less confident with 
interpreting results and counseling patients.  
3.4.4 Study Limitations and Future Directions 
This study provided new information on oncology providers’ genetic testing practices for 
patients with EOC, but several limitations exist. The sample may not be truly representative of all 
oncology providers, as there was a low response rate. The results may also be subject to response 
bias, as providers who are more interested or more confident in cancer genetics may have been 
more inclined to respond to the survey. Finally, this survey was descriptive in nature, and so 
underlying causes were not able to be examined.  
In spite of the limitations, the results of this study are encouraging and suggest that 
mainstreaming genetic testing for patients with EOC by oncology providers is an achievable 
service delivery model. Future studies should continue to delve into this pathway by examining 
providers’ genetics knowledge and the appropriateness of testing and referrals. More specific 
questions, perhaps with case scenarios or general knowledge questions, could help to elicit whether 
providers are accurately ordering, interpreting, and acting on genetic information. It would also be 
of interest to learn more about why the trends observed in this study exist. For example, with such 
a high percentage of providers always ordering testing, one would expect a higher percentage of 
patients to have received testing. Future studies can help to determine if testing rates have 
dramatically increased in recent years or if there is a significant absence of follow-though with 
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genetic test orders. Additionally, it would be of interest to determine the context that somatic 
testing is being ordered. Are providers ordering it alone, or prior to or after germline testing? Is a 
particular method more cost effective? Examining answers to questions such as these can help to 
improve this oncologist-led alternative service delivery pathway and increase access to genetics 
services. 
3.5 Conclusion 
As up to 25% of epithelial ovarian cancer diagnoses have an underlying genetic 
predisposition, accessible genetic testing is crucial to appropriately guide treatment for these 
patients. This study adds to the growing body of evidence that oncologist-led genetic testing for 
patients with EOC is a potentially feasible alternative service delivery model.  The majority of 
oncology providers are ordering multi-gene testing for this patient population and most commonly 
are doing so at diagnosis, in concordance with current NCCN and ASCO guidelines. Additionally, 
most providers who order testing independently are still referring patients to cancer genetics 
services, which can help to address patient emotions and risk to family members in more detail 
when necessary. Genetics educational support has been consistently shown to be highly desired, 
and results of this study suggest that genetics talks at conferences and continuing education events 
are popular modalities. Overall, oncologist-led genetic testing for patients with EOC with 
appropriate referrals to genetics services appears to be an achievable way to increase access to 
genetics services, but further research is necessary to tease out differences in provider confidence 
and investigate reasons for trends observed in this study. 
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4.0 Relevance to Genetic Counseling and Public Health 
The implications of this study’s results extend into both genetic counseling and public 
health. Assessing and monitoring community needs is the first essential service of public health. 
It is well-established that patients with epithelial ovarian cancer require genetics services for 
comprehensive care. The Center for Disease Control considers both Hereditary Breast and Ovarian 
Cancer syndrome and Lynch syndrome to be Tier 1 genomic conditions; there is significant 
evidence that identifying individuals with these conditions can have a significant public health 
impact.135 The shortage of genetics healthcare professionals necessitates alternative service 
delivery models in order to increase access to genetics services. Some service models can still 
incorporate genetics professionals themselves, such as telephone, telemedicine, pre-recorded 
videos, or group genetic counseling.107 However, these models alone still cannot meet the current 
demand. If every patient diagnosed with EOC should be offered genetic testing, then genetic 
testing cannot be solely completed by genetics professionals. 
This study sought to investigate a potential solution to the low percentage of genetic testing 
among patients with EOC, which reflects the second essential service of public health. The low 
rate of genetic testing is a hazard affecting these patients, as tailored treatment opportunities could 
be missed and at-risk family members may not be appropriately identified.17 The results of this 
study suggest that oncologist-led genetic testing for patients with EOC is a feasible alternative 
service delivery model, with 85% of gynecologic oncology providers always ordering testing for 
these patients. Supporting this service pathway has the potential to improve testing accessibility 
and increased testing rates, which in turn could lead to improved health outcomes for patients and 
their families.  
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 Within public health, there are three core functions: assessment, policy development, and 
assurance. This study assessed how oncology providers are using genetic testing in their practice 
and how confident they feel about different aspects of cancer genetics. This data is critical 
information that can be used to identify aspects of this service model that are working well and 
aspects that require targeted outreach to improve the process. This survey demonstrated that 
providers are generally ordering multi-gene panel testing at diagnosis for these patients, which is 
in compliance with current guidelines. Additionally, providers were very confident in their ability 
to know which patients require a referral to cancer genetics services. Providers were generally less 
confident in taking a detailed family history, so educational outreaches can strive to highlight the 
importance of family history and the familial implications of genetic test results. Addressing the 
aspects of genetics services that providers struggle with helps to assure that oncologist-led genetic 
testing delivers appropriate care. 
This study provides valuable information about the current genetic testing practice of 
gynecologic oncology providers. Future studies can continue to explore this practice by 
investigating provider knowledge and the appropriateness of referrals. Cancer genetic 
professionals have a key role to play in supporting this service pathway. They can help to educate 
and assist providers with questions that arise during the testing process. Furthermore, as referrals 
for positive or unclear results are a pivotal aspect of this service model, cancer genetics 
professionals are essential for comprehensive care of patients and their family members. The 
public health impact that this service model could provide is significant and warrants additional 
investigation. 
 49 




Appendix B Survey Content 
This study is being conducted by Megan Czekalski, a genetic counseling student at the University 
of Pittsburgh, for the completion of her thesis project. The purpose of this research study is to 
investigate current practices by oncology providers regarding cancer genetic testing for patients 
with epithelial ovarian cancer. We are surveying all members of the Society of Gynecologic 
Oncologists with this brief questionnaire, which will take approximately 15 minutes to complete. 
The survey collects information on your background (e.g. specialty, years of experience, etc.) and 
how you incorporate genetic testing in your practice. There are no foreseeable risks associated 
with this project, nor are there any direct benefits to you. You will not receive any payment for 
participation. Your responses will not be identifiable in any way, and all responses are confidential. 
Your participation is voluntary, and you may discontinue answering the survey questions at any 
time. Should you have any questions, you can contact Megan Czekalski at mac547@pitt.edu. 
 




oDecline to answer  
 
 
Q2 Over the past year, approximately what percentage of your total practice involved patients 
diagnosed with epithelial ovarian cancer? 









Many of the following questions will ask about genetic testing in your practice. For the purposes 
of this survey, we are interested in germline (hereditary) genetic testing only. Unless otherwise 
specified, only include somatic (tumor) genetic testing if germline results are also reported.  
 
 









Q4 When did you typically order genetic testing for patients with epithelial ovarian cancer in the 
past year? Select all that apply. 
▢At diagnosis  
▢Before beginning chemotherapy  
▢After beginning chemotherapy  






Q5 What kind of genetic testing did you typically order for patients with epithelial ovarian cancer 
in the past year? Select all that apply. 
▢BRCA1/2 testing  
▢Mismatch repair gene testing (e.g. MLH1, PMS2, MSH2, MSH6; typically associated 
with Lynch syndrome)  
▢Panel testing (e.g. multi-gene testing that examines BRCA1/2 and other genes at the 
same time)  
▢Somatic testing (with reported germline mutations)  
▢Somatic testing (without reported germline mutations)  





Q6 What barriers hinder or prevent you from ordering genetic testing for patients with epithelial 
ovarian cancer? Select all that apply. 
▢I do not think genetic testing is necessary  
▢It will not change medical management for the patient  
▢I am concerned about insurance discrimination against patients  
▢I am concerned about insurance not covering genetic testing  
▢My patient was not interested  
▢I am confused by genetic testing  
▢Other (please specify): ________________________________________________ 




Q7 How often have you used genetic testing results to guide the treatment (e.g. chemotherapy) of 










Q8 How often have you referred patients with epithelial ovarian cancer to cancer genetics services 







Q9 When did you typically refer patients with epithelial ovarian cancer to cancer genetics services 
in the past year? Select all that apply. 
▢At diagnosis  
▢Before genetic testing for pre-test counseling  
▢After ordering genetic testing if there is a positive result  
▢After ordering genetic testing if there is an uncertain result  
▢After ordering genetic testing if there is a negative result  






Q10 What barriers hinder or prevent you from referring patients with epithelial ovarian cancer to 
cancer genetics services? Select all that apply. 
▢I provide the needed services to patients  
▢I am concerned about insurance discrimination against patients  
▢I am concerned about insurance not covering genetic counseling or testing  
▢I do not want to burden my patients with additional appointments  
▢My patient was not interested  
▢There are no cancer genetics services in the area  
▢I do not know who to refer my patients to  
▢I am confused about these services  
▢Other (please specify): ________________________________________________ 





Q11 Have you completed any training or continuing education in genetics? Select all that apply. 
▢Completed course(s) in genetics in medical school  
▢Completed a residency or fellowship in genetics  
▢Watched webinar(s)  
▢Attended talk(s) at conference(s) about genetics  
▢Attended Continuing Education event(s)  
▢Taken formal course(s) in genetics after medical school  
▢Obtained certification(s) in genetics  
▢Other (please specify): ________________________________________________ 




Q12 How confident are you in taking a detailed, 3-generation family history? 
oNot confident  
oSomewhat confident  
oVery confident  





Q13 How confident are you in ordering genetic testing? 
oNot confident  
oSomewhat confident  
oVery confident  




Q14 How confident are you in interpreting all possible genetic testing results (e.g. positive, 
negative, or a VUS)?  
oNot confident  
oSomewhat confident  
oVery confident  




Q15 How confident are you in counseling a patient on the meaning of their genetic testing results? 
oNot confident  
oSomewhat confident  
oVery confident  





Q16 How confident are you in deciding which patients should be referred to cancer genetics? 
oNot confident  
oSomewhat confident  
oVery confident  




Q17 What is your current job title? 
oGynecologic oncologist  
oMedical oncologist  
oSurgical oncologist  
oNurse practitioner  
oPhysician assistant  
oRegistered nurse  
oOther (please specify): ________________________________________________ 





Q18 What is your primary area of medical practice? 
oGynecology/obstetrics  
oInternal medicine  
oFamily practice  
oOther (please specify): ________________________________________________ 








▢Other (please specify): ________________________________________________ 





Q20 Which of the following best describes your practice setting? Select all that apply.  
▢Private practice  
▢Group practice  
▢Hospital based  
▢Academic center  
▢Other (please specify): ________________________________________________ 








o30 or more  





Q22 Which category below includes your age? 
o29 or younger  
o30-49  
o50-69  
o70 years or older  








oOther (please specify): ________________________________________________ 





Q24 What ethnicity do you identify as? Select all that may apply. 
▢American Indian or Alaskan Native  
▢Asian  
▢Black or African-American  
▢Native Hawaiian or other Pacific islander  
▢White  
▢Other (please specify): ________________________________________________ 




Q25 Are you of Hispanic, LatinX, or Spanish origin? 
oYes  
oNo  
oDecline to answer  
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Appendix C Recruitment E-mail 
Dear SGO member, 
  
I’m reaching out to you today to invite you to participate in a research study. This study is being 
conducted by Megan Czekalski, a second-year genetic counseling student at the University of 
Pittsburgh. 
 
She is conducting an online, anonymous survey as part of her master’s thesis project entitled 
“Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A 
Survey of Current Practice.” This research project seeks to investigate current practices by 
oncology providers regarding cancer genetic testing for patients with epithelial ovarian cancer. 
We are surveying all members of the Society of Gynecologic Oncologists with this brief 
questionnaire, which will take approximately 15 minutes to complete.  
 
The survey collects information on your background (e.g., specialty, years of experience, etc.) 
and how you incorporate genetic testing in your practice.  There are no foreseeable risks 
associated with this project, nor are there any direct benefits to you. You will not receive any 
payment for participation. Your responses will not be identifiable in any way, and all responses 
are confidential. Your participation is voluntary, and you may discontinue answering the survey 
questions at any time. 
 
To participate in the survey, please use this link: 
https://pitt.co1.qualtrics.com/jfe/form/SV_8cEm74MY0W2mMJv 
 
Disclaimer: This survey is not in connection to the Society of Gynecologic Oncology. 
 
This project is being conducted in partial fulfillment of a Master of Science in Genetic 
Counseling at the University of Pittsburgh. This study has been approved by the University of 
Pittsburgh Institutional Review Board, STUDY20070321. 
 
Thank you for your time and participation. Should you have any comments or questions, please 
feel free to contact Megan at mac547@pitt.edu. You may also reach out to other members of the 
thesis committee:  
Rachelle C. Huziak, MS, CGC: huziakr@upmc.edu  
Phuong Mai, MD, MS: maip@upmc.edu   






Appendix D Statistical Analysis 
CONFIDENCE TAKING FAMILY HISTORY 
 
CONFIDENCE ORDERING GENETIC TESTING 
 
           Fisher's exact =                 0.968
                         144.0        4.0       21.0       169.0 
             Total         144          4         21         169 
                                                                
                          62.2        1.7        9.1        73.0 
    Very confident          63          2          8          73 
                                                                
                          63.1        1.8        9.2        74.0 
Somewhat confident          62          2         10          74 
                                                                
                          18.7        0.5        2.7        22.0 
     Not confident          19          0          3          22 
                                                                
               fhx      Always      Never         OS       Total
                               order_group
stage 1:  enumerations = 0
stage 2:  enumerations = 1
stage 3:  enumerations = 1
Enumerating sample-space combinations:
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
. tab fhx order_group, exact exp
           Fisher's exact =                 0.008
                         141.0        4.0       20.0       165.0 
             Total         141          4         20         165 
                                                                
                          82.0        2.3       11.6        96.0 
    Very confident          86          1          9          96 
                                                                
                          44.4        1.3        6.3        52.0 
Somewhat confident          43          0          9          52 
                                                                
                          14.5        0.4        2.1        17.0 
     Not confident          12          3          2          17 
                                                                
        order_test      Always      Never         OS       Total
                               order_group
stage 1:  enumerations = 0
stage 2:  enumerations = 14
stage 3:  enumerations = 1
Enumerating sample-space combinations:
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
. tab order_test order_group, exact exp
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CONFIDENCE INTERPRETING TESTING 
 
 




           Fisher's exact =                 0.005
                         145.0        4.0       21.0       170.0 
             Total         145          4         21         170 
                                                                
                          81.0        2.2       11.7        95.0 
    Very confident          87          2          6          95 
                                                                
                          57.1        1.6        8.3        67.0 
Somewhat confident          54          1         12          67 
                                                                
                           6.8        0.2        1.0         8.0 
     Not confident           4          1          3           8 
                                                                
    interpret_test      Always      Never         OS       Total
                               order_group
stage 1:  enumerations = 0
stage 2:  enumerations = 12
stage 3:  enumerations = 1
Enumerating sample-space combinations:
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
. tab interpret_test order_group, exact exp
           Fisher's exact =                 0.002
                         145.0        4.0       21.0       170.0 
             Total         145          4         21         170 
                                                                
                          82.7        2.3       12.0        97.0 
    Very confident          91          2          4          97 
                                                                
                          58.9        1.6        8.5        69.0 
Somewhat confident          51          2         16          69 
                                                                
                           3.4        0.1        0.5         4.0 
     Not confident           3          0          1           4 
                                                                
      counsel_test      Always      Never         OS       Total
                               order_group
stage 1:  enumerations = 0
stage 2:  enumerations = 12
stage 3:  enumerations = 1
Enumerating sample-space combinations:
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
. tab counsel_test order_group, exact exp
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CONFIDENCE DECIDING WHICH PATIENTS TO REFER 
            Fisher's exact =                 1.000
                         145.0        4.0       21.0       170.0 
             Total         145          4         21         170 
                                                                
                         123.7        3.4       17.9       145.0 
    Very confident         123          4         18         145 
                                                                
                          21.3        0.6        3.1        25.0 
Somewhat confident          22          0          3          25 
                                                                
             refer      Always      Never         OS       Total
                               order_group
stage 1:  enumerations = 0
stage 2:  enumerations = 0
stage 3:  enumerations = 1
Enumerating sample-space combinations:
                      
  expected frequency  
      frequency       
                      
  Key                 
                      
. tab refer order_group, exact exp
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